sunday 23 sEpTEMbEr - ehmtic 2012

EHMTIC20I2
European Headache and Migraine Trust International Congress
P208 Efficacy of MAP0004 in treating severe migraine
Kori, S.; Connors, E.; Zhou, J.; Lu, B.; Borland, S.
MAP Pharmaceuticals, United States
P209 EUROLIGHT project: impact of primary headache disorders from a population-based study conducted in Pavia
Allena, M. 1 ; Tassorelli, C. 1 ; Carugno, B. 2 ; De Icco, R. 1 ; Andree, C. 3 ; Nappi, G. 1
1 HSC, Headache Science Centre, IRCCS “National Neurological Institute C. Mondino” Foundation and University of Pavia
and UCADH, Italy; 2 ASL, Azienda Sanitaria Locale of Pavia area, Pavia, Italy; 3 CRP, Centre Recherche Publique, Luxembourg,
Luxembourg
P210 The effect of sumatriptan on cephalic arteries - 3T MR-angiography study in healthy volunteers
Amin, F.M. 1 ; Asghar, M.S. 1 ; Ravneberg, J.W. 1 ; de Koning, P.J.H. 2 ; Larsson, H.B.W. 3 ; Olesen, J. 1 ; Ashina, M. 1
1 Danish Headache Center & Dept. of Neurology, Denmark; 2 Division of Image Processing, Netherlands; 3 Functional Imaging Unit,
Department of Diagnostic, Glostrup Hospital, Denmark
P211 Bilateral jaw dislocation following botulinim toxin type A treatment for chronic migraine
Forbes, R.B.; Devenney, E.
Craigavon Area Hospital, United Kingdom
P212 Consistency vs. switching triptan treatment and headache-related disability: Results of the American
migraine prevalence & prevention study
Buse, D.C. 1 ; Serrano, D. 2 ; Kori, S. 3 ; Cunanan, C. 4 ; Manack, A.N. 4 ; Reed, M.L. 2 ; Lipton, R.B. 1
1 2 3 Albert Einstein College of Medicine, United States; Vedanta Research, United States; MAP Pharmaceuticals, United States;
4Allergan Inc., United States
P213 Prophylactic treatments of migraine and GPs in the north of France: Evaluation of practices
Christian, C.L.
Service de Neurologie et Pathologie Neurovasculaire, France
P214 Adding acute treatments for patients on triptans: Results of the American Migraine Prevalence & Prevention
(AMPP) study
Lipton, R.B. 1 ; Serrano, D. 2 ; Kori, S. 3 ; Cunanan, C. 4 ; Manack, A.N. 4 ; Reed, M.L. 2 ; Buse, D.C. 1
1 2 3 Albert Einstein College of Medicine, United States; Vedanta Research, United States; MAP Pharmaceuticals, United States;
4Allergan Inc., United States
P215 Zonisamide is effective in the preventive therapy of chronic migraine
Belvis, R.; Aceituno, A.; Martinez-Corral, M.
Dexeus University Insitute, Spain;
P216 Real-world economic impact of onabotulinumtoxina in patients with chronic migraine
Rothrock, J.F. 1 ; Bloudek, L.M. 2 ; Houle, T.T. 3 ; Andress-Rothrock, D. 4 ; Hanlon, C. 1 ; Varon, S.F. 5
1 2 3 The University of Alabama School of Medicine, Birmingham, AL, United States; Allergan, Inc., Irvine, CA, United States; Wake
Forest University School of Medicine, Winston-Salem, NC, United States; 4University of Alabama Headache, Treatment and
Research Program, Birmingham, AL, United States; 5Allergan, Inc., Irvine, CA, United States
59